News Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
34.9 ^CNY	-2.79%		-1.33%	+6.76%

May. 07	Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	CI
Apr. 29	Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	May. 07	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China	Apr. 08	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment	Apr. 04	MT
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting	Mar. 19	CI
Mabwell Scraps Licensing Deal With Yangtze River Pharma	Feb. 27	MT
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology	Feb. 21	CI
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711	Feb. 20	CI
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5%	Feb. 18	MT
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	Jan. 17	CI
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA	Dec. 19	CI
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial	Dec. 11	CI
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug	Dec. 08	MT
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs	23-10-23	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-18	CI
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor	23-09-28	CI
Mabwell Bioscience Co., Ltd.(XSSC:688062) added to S&P Global BMI Index	23-09-18	CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Mabwell Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND	23-06-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

Summary

Filters